Milos Janicek, MD, PhD, serves as an Associate Professor of Radiology in Body Imaging at the Boston University School of Medicine. For several years he served as Section Chief in the department of Radiology. As a former fellow at the Dana Farber Cancer Institute, he developed a special interest in tumor Imaging and infrared imaging application in tumor biology and continues to conduct research in these subfields. Dr. Janicek holds duel certification in diagnostic radiology and nuclear medicine by the American Board of Radiology.
- Palacký University, Olomouc, MD
- Jan Evangelista Purkyne University, PhD
- Published on 8/1/2014
Zhu V, de Las Morenas A, Janicek M, Hartshorn K. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol. 2014 Aug; 5(4):E84-7. PMID: 25083313.
- Published on 9/20/2011
Janicek MJ, Camaya VM. Probably benign findings, BIRADS category 3 (MR-Bi3), on magnetic resonance imaging of the breast (BrMR): Is repeated MRI an alternative to biopsy? J Clin Oncol. 2011 Sep 20; 29(27_suppl):21. PMID: 27958027.
- Published on 5/20/2011
Janicek MJ, Camaya VM, Naddaff D. Value of close follow-up for "probably benign findings," BIRADS category 3 (MR-Bi3), on magnetic resonance imaging of the breast (BrMR). J Clin Oncol. 2011 May 20; 29(15_suppl):e11060. PMID: 28023441.
- Published on 4/8/2011
Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25. PMID: 24673925.
- Published on 6/20/2010
Teneriello MG, Gordon AN, Lim P, Janicek M. Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report. J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA5008. PMID: 27937443.
- Published on 6/1/2005
Mendelson DS, Brewer M, Janicek M, Breitenbach E, Barrett E, Hamilton M, Ptazynski M, van Duym C, Gordon M. Phase I study of OSI-211 (liposomal lurtotecan) in combination with liposomal doxorubicin (LD) every 3 weeks in patients (pts) with advanced solid tumors; final analysis suggests benefit in refractory ovarian cancer (OC). J Clin Oncol. 2005 Jun; 23(16_suppl):2074. PMID: 27946920.
- Published on 12/1/2003
Janicek MJ, Demetri G, Janicek MR, Shaffer K, Fauci MA. Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography. Technol Cancer Res Treat. 2003 Dec; 2(6):571-8. PMID: 14640768.
- Published on 9/15/2002
Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84. PMID: 12228197.
- Published on 8/15/2002
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80. PMID: 12181401.
- Published on 3/1/2002
Oh WK, Loda M, Kantoff PW, Janicek M. Progressive sclerosis of isolated foot metastasis of prostate cancer. J Urol. 2002 Mar; 167(3):1392. PMID: 11832744.
View 23 more publications: View full profile at BUMC